Sensus Healthcare (NASDAQ:SRTS) Director Eric Sachetta Purchases 37,537 Shares of Stock

Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Eric Sachetta bought 37,537 shares of the stock in a transaction dated Friday, August 28th. The stock was purchased at an average price of $3.44 per share, with a total value of $129,127.28. Following the purchase, the director owned 267,480 shares in the company, valued at $920,131.20. This trade represents a 16.32% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Eric Sachetta also recently made the following trade(s):

• On Monday, August 31st, Eric Sachetta purchased 27,304 shares of Sensus Healthcare stock. The stock was purchased at an average cost of $3.54 per share, for a total transaction of $96,656.16.
• On Thursday, August 27th, Eric Sachetta acquired 10,925 shares of Sensus Healthcare stock. The stock was purchased at an average price of $3.18 per share, with a total value of $34,741.50.
• On Wednesday, August 26th, Eric Sachetta acquired 9,708 shares of Sensus Healthcare stock. The stock was purchased at an average price of $3.29 per share, with a total value of $31,939.32.
• On Monday, August 24th, Eric Sachetta acquired 34,697 shares of Sensus Healthcare stock. The shares were purchased at an average cost of $3.25 per share, with a total value of $112,765.25.

Sensus Healthcare Stock Up 3.4%

Shares of NASDAQ:SRTS traded up $0.12 during midday trading on Monday, reaching $3.64. The company’s stock had a trading volume of 102,018 shares, compared to its average volume of 65,130. The firm has a 50 day moving average of $3.05 and a 200-day moving average of $3.51. The firm has a market capitalization of $59.91 million, a P/E ratio of -3.87 and a beta of 1.10. Sensus Healthcare, Inc. has a 12-month low of $2.66 and a 12-month high of $5.49.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.41). The business had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $4.60 million. Sensus Healthcare had a negative net margin of 88.45% and a negative return on equity of 21.57%.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Citigroup restated a “buy” rating on shares of Sensus Healthcare in a research note on Friday, May 8th. Weiss Ratings cut Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, August 18th. Lake Street Capital reduced their price target on Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating for the company in a report on Friday, August 14th. Wall Street Zen cut shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Finally, Alliance Global Partners reissued a “buy” rating on shares of Sensus Healthcare in a research report on Monday, August 17th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $5.83.

Hedge Funds Weigh In On Sensus Healthcare

Several hedge funds and other institutional investors have recently bought and sold shares of SRTS. Pacific Ridge Capital Partners LLC grew its stake in shares of Sensus Healthcare by 21.8% in the fourth quarter. Pacific Ridge Capital Partners LLC now owns 698,634 shares of the company’s stock worth $2,781,000 after acquiring an additional 125,245 shares during the period. Geode Capital Management LLC boosted its holdings in Sensus Healthcare by 3.5% in the fourth quarter. Geode Capital Management LLC now owns 158,240 shares of the company’s stock worth $630,000 after purchasing an additional 5,316 shares during the last quarter. Sachetta LLC boosted its holdings in Sensus Healthcare by 6.8% in the fourth quarter. Sachetta LLC now owns 148,508 shares of the company’s stock worth $591,000 after purchasing an additional 9,500 shares during the last quarter. Greenline Wealth Management LLC bought a new stake in Sensus Healthcare in the 4th quarter worth approximately $513,000. Finally, North Star Investment Management Corp. bought a new stake in Sensus Healthcare in the 1st quarter worth approximately $500,000. Institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.